https://www.businesswire.com/news/home/20260226222582/ja 2026-02-28T20:52:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227492966/fr 2026-02-28T17:54:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227171324/it 2026-02-28T17:54:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227717679/es 2026-02-28T17:54:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227583399/nl 2026-02-28T17:54:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227781828/de 2026-02-28T17:53:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260228796958/en/AARD-Investors-Have-Opportunity-to-Join-Aardvark-Therapeutics-Inc.-Fraud-Investigation-With-the-Schall-Law-Firm 2026-02-28T16:46:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260228266433/pt 2026-02-28T16:15:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260228159491/es 2026-02-28T16:15:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260228025853/en/KEYTRUDA-pembrolizumab-Plus-WELIREG-belzutifan-Given-as-Adjuvant-Therapy-Reduced-the-Risk-of-Disease-Recurrence-or-Death-by-28-Compared-to-KEYTRUDA-Monotherapy-in-Certain-Patients-With-Earlier-Stage-Renal-Cell-Carcinoma-RCC 2026-02-28T15:05:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260228417897/en/WELIREG-belzutifan-Plus-LENVIMA-lenvatinib-Reduced-the-Risk-of-Disease-Progression-or-Death-by-30-Compared-to-Cabozantinib-in-Certain-Previously-Treated-Patients-With-Advanced-Renal-Cell-Carcinoma-RCC 2026-02-28T15:00:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260228505745/en/Berkshire-Hathaway-Inc.-News-Release 2026-02-28T13:00:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227334210/en/The-Cannabist-Company-Further-Extends-Forbearance-Agreement-With-Senior-Noteholders 2026-02-28T01:51:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227374991/en/KIRIN-HYOKETSU-Expands-into-U.S.-RTD-Market-with-Local-Production 2026-02-28T01:31:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227649072/en/REMINDER-Coreweave-Inc.-Investors-With-Significant-Losses-Must-Act-By-March-13-2026 2026-02-28T01:00:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227265237/en/CWH-INVESTOR-ALERT-Kirby-McInerney-LLP-Investigates-Potential-Claims-Involving-Camping-World-Holdings-Inc. 2026-02-28T01:00:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227314794/en/EPAM-SYSTEMS-INC.-INVESTOR-ALERT-Kirby-McInerney-LLP-Announces-Investigation-Into-Potential-Securities-Fraud 2026-02-28T01:00:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227486576/en/Biocytogen-Announces-Clinical-Milestone-with-First-Patient-Dosed-in-Phase-1-Trial-of-IDEAYAs-First-in-Class-B7H3PTK7-Bispecific-TOP1-ADC-IDE034 2026-02-28T00:00:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227206909/en/Biocytogen-Announces-Clinical-Milestone-with-First-Patient-Dosed-in-Phase-1-Trial-of-IDEAYAs-First-in-Class-B7H3PTK7-Bispecific-TOP1-ADC-IDE034 2026-02-28T00:00:00.000Z weekly 0.5 https://www.businesswire.com/news/home/20260227146095/zh-CN 2026-02-28T00:00:00.000Z weekly 0.5